Industry-Supported Presentation Theaters
Wednesday, April 26, 2023
Time: 12:35 pm – 1:35 pm
Title: Discover the Impact of GEMTESA, An Effective OAB Treatment: A Fresh Look at OAB Management in Long-Term Care Settings
Presenter: Elizabeth Coon-Nguyen, MD
GEMTESA is a β3 (beta 3)-adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
Sponsored by: Urovant Sciences, Inc.
»Presentation theater and lunch will be provided. Attendees will be admitted on a ﬁrst-come basis.
Friday, April 28, 2023
Time: 7:00 am – 8:00 am
Title: Tardive Dyskinesia: Clinical Considerations in Older Adults and Advances in Therapeutic Management
Presenter: Kaylee Mehlman, PharmD, RPh, BCGP, FASCP, Contact
Studies have shown that older adults receiving antipsychotics may have an increased risk for tardive dyskinesia (TD), even when treated with lower doses and shorter length of treatment. This presentation will provide an overview of TD, including the risk implications and impact of TD pertaining to older patients. Learn about TD management as this session examines the current evidence for various treatment strategies and the pharmacology of appropriate therapies for TD.
Sponsored by: Neurocrine Biosciences.
»Presentation theater and breakfast will be provided. Attendees will be admitted on a ﬁrst-come basis.
Saturday, April 29, 2023
Time: 7:00 am – 8:00 am
Registration and Breakfast: 6:30 AM – 6:55 AM
Satellite: 6:55 AM – 7:55 AM
CH: Breakfast Symposium (1.0 CH)*
Title: Agitation Associated with Alzheimer's Disease: Current Best Practices and Planning for the Future
This session will discuss current best practices for the pharmacologic management of agitation associated with Alzheimer’s disease and what’s emerging in this area. The pharmacology, efficacy, and safety of current treatment options and their risks and benefits in this patient population will be discussed and demonstrated through patient cases. Emerging treatment options will also be covered, including the latest evidence on what may be on the horizon to treat this debilitating complication of Alzheimer’s disease.
Sponsored by: Clinical Care Options, LLC
*Contact hours awarded by Clinical Care Options, LLC.
»Breakfast will be provided. Attendees will be admitted on a ﬁrst-come basis.